GLAND
GLAND PHARMA LIMITEDHealthcare
LTP
2,916.1
CHG · %
+18.7 (+0.65%)
VOL · TODAY
19.40K
PREV CLOSE
2,897.4
Today's range2,882 · 2,924.4
2,916.1
52-week range1,573.6 · 3,042
2,916.1
Loading candles…
Gland Pharma Limited, established in Hyderabad, India in 1978, is a pharmaceutical company focused on the development, manufacturing, and marketing of complex generic injectable products. Operating primarily through a business-to-business model, the company offers contract development and manufacturing organization (CDMO) services alongside the out-licensing of its generic injectable portfolio. Its product range includes generic injectables and complex injectables such as oncology, ophthalmic, and biologic formulations. Gland Pharma serves markets including the United States, Europe, Canada, Australia, India, and other regions. In 2023, the company acquired Cenexi, a move that facilitated the expansion of its manufacturing capabilities into Europe. Gland Pharma is promoted by Shanghai Fosun Pharma, a global pharmaceutical major, and operates primarily within the pharmaceutical and injectable industries, with headquarters in Hyderabad.
GLAND is not part of any active scan today.
This page is a live market overview for GLAND PHARMA LIMITED (GLAND) on the NSE. As a listed security, GLAND PHARMA LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for GLAND before placing trades on tick2trade.
As of the latest feed, GLAND last traded at ₹2,916.1 on NSE, up ₹18.7 (0.65%) from the previous close of ₹2,897.4. Today's session range is ₹2,882 – ₹2,924.4, against a 52-week band of ₹1,573.6 – ₹3,042. Traded volume today stands at 19.40K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for GLAND in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether GLAND is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for GLAND PHARMA LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in GLAND. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated GLAND option chain page linked from this overview.
// similar in healthcare322 total